Size of a Newborn Eye



The recommended dose for ROP newborn is 0.65 mg which is half the dose of an adult. This dose suggests that a newborn eye is half the size of an adult’s eye. But this is not the case as this chapter will demonstrate. It is in fact much smaller which means that the dose of 0.65 mg is too high for a neonate.


Dose Avastin ROP Size of newborn eye Size Neonate 


  1. 1.
    Ehlers N, Mathiesen ME, Andersen H. The prenatal growth of the human eye. Acta Ophthalmol (Kbh). 1968;46:329–49.CrossRefGoogle Scholar
  2. 2.
    Harder BC, Baltz SV, Jonas JB, Schlichtenbrede FC. Intravitreal bevacizumab for retinopathy of prematurity. J Ocul Pharmacol Ther. 2011;27:623–7.CrossRefGoogle Scholar
  3. 3.
    Hillier RJ, Connor AJ, Shafiq AE. Ultra-low-dose intravitreal bevacizumab for the treatment of retinopathy of prematurity: a case series. Br J Ophthalmol. 2018;102(2):260–4. Epub 2017 June 27CrossRefPubMedGoogle Scholar
  4. 4.
    Larsen JS. The sagittal growth of the eye. Acta Ophthalmol. 1971;49:441–4.CrossRefGoogle Scholar
  5. 5.
    Lorenz B. Kommentar: anti-VEGF-Einsatz gut abwägen. Klin Monatsbl Augenheilkd. 2011;225:488–90.Google Scholar
  6. 6.
    Matsuyama K, Ogata N, Matsuoka M, Takahashi K, Nishimura T. Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab. Br J Ophthalmol. 2010;94(9):1215–8.CrossRefGoogle Scholar
  7. 7.
    Mintz-Hittner HA, Kennedy KA, Chuang AZ, BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for salyage 3+ retinopathy of prematurity. N Engl J Med. 2011;364:603–15.CrossRefGoogle Scholar
  8. 8.
    Şahin A, Gürsel-Özkurt Z, Şahin M, Türkcü FM, Yıldırım A, Yüksel H. Ultra-low dose of intravitreal bevacizumab in retinopathy of prematurity. Ir J Med Sci. 2018;187:417–21.CrossRefGoogle Scholar
  9. 9.
    Spandau U. What is the optimal dosage for intravitreal bevacizumab for retinopathy of prematurity? Acta Ophthalmol. 2013;91(2):e154.CrossRefGoogle Scholar
  10. 10.
    Wallace DK, Kraker RT, Freedman SF, Crouch ER, Hutchinson AK, Bhatt AR, Rogers DL, Yang MB, Haider KM, VanderVeen DK, Siatkowski RM, Dean TW, Beck RW, Repka MX, Smith LE, Good WV, Hartnett ME, Kong L, Holmes JM, Pediatric Eye Disease Investigator Group (PEDIG). Assessment of lower doses of intravitreous bevacizumab for retinopathy of prematurity: a phase 1 dosing study. JAMA Ophthalmol. 2017;135:654–6.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.OphthalmologyUniversity of Uppsala OphthalmologyUppsalaSweden
  2. 2.Department of OphthalmologySamsung Medical Center, Sungkyunkwan UniversitySeoulSouth Korea

Personalised recommendations